

---

Sunday March 3, 11:04 am Eastern Time

## Medinol stops stent supplies to Boston Scientific

TEL AVIV, March 3 (Reuters) - Israeli medical stent maker Medinol Ltd said on Sunday it had told Boston Scientific (NYSE:[BSX](#) - [news](#)) it was ending its supply of stents due to ``continuing breaches" of the companies' 1995 agreement.

Under the agreement, Medinol makes the stents while Boston Scientific has exclusive worldwide distribution rights, Medinol said in a statement.

Medinol alleged that the U.S. firm had breached important parts of the agreement during the past year concerning royalties, intellectual property rights and had failed to bring Medinol's new generation of stents to market.

The two companies are fighting a court case in New York brought last year by Medinol concerning the alleged breaches, Medinol said.

Boston Scientific denied Medinol's claims in a statement. ``Medinol's attempt to terminate the supply agreement is improper and invalid," spokesman Paul Donovan said.

``Boston Scientific has not breached this agreement so Medinol's action is baseless. We will, of course, challenge this impermissible action. Boston Scientific considers the supply agreement to be in full force and effect."

Boston Scientific's shares ended up 3.9 percent at \$23.24 on the New York Stock Exchange on Friday just below its year-high of \$27.89 but well above its year-low of \$14.56.

[Email this story](#) - [Most-emailed articles](#) - [Most-viewed articles](#)

---

**More Quotes and News:** [Boston Scientific Corp \(NYSE:BSX - news\)](#)

**Related News Categories:** [medical/pharmaceutical](#), [US Market News](#)

---

[Help](#)